SLLK, Control Peptide for TSP1 Inhibitor(TFA)

C23H42F3N5O8

H2O : 135 mg/mL (235.36 mM; Need ultrasonic)

Others

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor. In Vivo: Akita mice treated with 30 mg/kg LSKL have significantly increased nephrin expression, greater than twofold, compared with renal lysates from either saline controls or SLLK-treated mice^[1].TGF-beta1 is significantly lower (0.10+/-0.01 pg/mL) in the plasma of mice receiving LSKL compared with that in plasma of mice receiving SLLK control peptide at day 42 (0.20+/-0.02 pg/mL; P=0.0001). MRNA expression is assessed in the suprarenal aortic lysates obtained from mice receiving SLLK and LSKL peptides^[2].